Inovio’s dMAb™ Platform moves ahead with positive data, patents and Gates Foundation grant
Inovio announced it has received the first two U.S. patents for its DNA-encoded monoclonal antibody technology (dMAb™) from the USPTO and has been awarded a $2.2 million grant from the Bill & Melinda Gates Foundation to advance its dMAb platform and new clinical delivery devices. October 17, 2018